Adwan Hamzah, Hammann Lars, Vogl Thomas J
Department of Diagnostic and Interventional Radiology, University Hospital, Goethe University Frankfurt, Theodor-Stern-Kai 7, 60590 Frankfurt, Germany.
J Clin Med. 2023 Mar 29;12(7):2560. doi: 10.3390/jcm12072560.
To evaluate the efficacy and safety of microwave ablation (MWA) as a treatment for recurrent hepatocellular carcinoma (HCC) after initial successful surgical resection.
This retrospective study included 40 patients (11 women and 29 men; mean age: 62.3 ± 11.7 years) with 48 recurrent lesions of HCC after initial surgical resection that were treated by percutaneous MWA. Several parameters including complications, technical success, local tumor progression (LTP), intrahepatic distant recurrence (IDR), overall survival (OS), and progression-free survival (PFS) were evaluated in order to investigate the safety and efficacy of MWA for these recurrent HCC lesions after surgical treatment.
All MWA treatments were performed without complications or procedure-related deaths. Technical success was achieved in all cases. Two cases developed LTP at a rate of 5%, and IDR occurred in 23 cases at a rate of 57.5% (23/40). The 1-, 2-, 3-, 4-, and 6-year OS rates were 97%, 89.2%, 80.3%, 70.2%, and 60.2%, respectively. The 1- and -year PFS rates were 50.2% and 34.6%, respectively.
MWA is effective and safe as a local treatment for recurrent HCC after initial surgical resection.
评估微波消融（MWA）作为初次手术切除成功后复发性肝细胞癌（HCC）治疗方法的有效性和安全性。
本回顾性研究纳入了40例患者（11例女性和29例男性；平均年龄：62.3±11.7岁），这些患者在初次手术切除后有48个复发性HCC病灶，接受了经皮MWA治疗。评估了包括并发症、技术成功率、局部肿瘤进展（LTP）、肝内远处复发（IDR）、总生存期（OS）和无进展生存期（PFS）等多个参数，以研究MWA对这些手术治疗后复发性HCC病灶的安全性和有效性。
所有MWA治疗均未出现并发症或与操作相关的死亡。所有病例均取得技术成功。2例发生LTP，发生率为5%，23例发生IDR，发生率为57.5%（23/40）。1年、2年、3年、4年和6年的OS率分别为97%、89.2%、80.3%、70.2%和60.2%。1年和2年的PFS率分别为50.2%和34.6%。
MWA作为初次手术切除后复发性HCC的局部治疗方法是有效且安全的。
